VivoSense, which develops wearable biometric sensors to collect and organize data from patients for clinical drug trials, raises a $25M Series A
Keerthi Vedantam / dot.LA :
Context & Ripple Effects
VivoSense's $25M Series A lands in a category that has been raising at scale since at least 2018, when Verana Health raised $30M led by GV to analyze clinical studies with big data. The thesis has since split into two layers: hardware-adjacent consumer players like Withings, whose $60M round supplied provider-facing health data, and trial-native platforms like [[a:957514|Biofourmis, which raised $100M from SoftBank's Vision Fund 2 specifically to test pharmaceutical drugs on medical wearables]].
What distinguishes VivoSense in this field is its position as a data organizer rather than a device maker or a virtual-trial operator — closer to what Evidation Health built with its $45M Series D for aggregating wearable data into virtual trials. The raise signals investors still see room for a dedicated sensor-to-endpoint layer between consumer hardware and pharma sponsors.
First-order effects
- Pharma sponsors running clinical trials gain a newly capitalized vendor for collecting and structuring wearable biometric data, giving them an alternative to building sensor pipelines in-house.
- VivoSense can now scale beyond pilot deployments and compete directly for the decentralized-trial budgets that Biofourmis and Evidation Health have been courting.
Second-order effects
- Incumbents like Biofourmis face pressure to differentiate: if sensor data collection becomes commoditized, their pricing power shifts toward analytics and regulatory-grade endpoint validation rather than hardware access.
- Consumer wearable makers such as Withings gain a larger institutional buyer base as clinical-grade intermediaries like VivoSense standardize how consumer-device data enters regulated trials.
Third-order effects
- If wearables keep proving out as trial endpoints, the industry structure moves toward a specialized middle layer — companies whose product is validated, organized biometric data rather than devices or drugs — reshaping how CROs and sponsors contract for evidence.
- Regulators will increasingly be asked to accept wearable-derived measurements as primary or secondary endpoints, making data provenance and validation standards the battleground for this entire funding category.
The trend: Clinical drug development is shifting from site-visit-based measurement to continuously collected wearable biometric data, with a dedicated venture-funded vendor layer forming between consumer device makers and pharma sponsors.